Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
AReMIS
Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
1 other identifier
observational
4,992
1 country
1
Brief Summary
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2013
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 21, 2013
CompletedFirst Posted
Study publicly available on registry
September 30, 2013
CompletedStudy Start
First participant enrolled
October 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2016
CompletedFebruary 24, 2017
February 1, 2017
2.4 years
August 21, 2013
February 23, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Medical information
History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors
At baseline visit
Drug exposure
Current exposure: within 24 hours (before date of recurrent MI). Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
Current
Drug exposure
Recent exposure: in the week (7 days) preceding the recurrent MI. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
Recent
Drug exposure
Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
Past
Secondary Outcomes (1)
Other medical events of interest
During follow-up (up to 12 months)
Study Arms (2)
Control group
Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
Case group
Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
Eligibility Criteria
Patients aged 18 years or more, both genders,with an acute coronary syndrome, agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.
You may qualify if:
- Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (1)
Research Site
Paris, France
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 21, 2013
First Posted
September 30, 2013
Study Start
October 1, 2013
Primary Completion
March 1, 2016
Study Completion
March 1, 2016
Last Updated
February 24, 2017
Record last verified: 2017-02